EUR 76.95
(0.59%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 147.78 Million EUR | -13.22% |
2022 | 170.3 Million EUR | -10.59% |
2021 | 190.46 Million EUR | -16.29% |
2020 | 227.53 Million EUR | 94.06% |
2019 | 117.24 Million EUR | -16.37% |
2018 | 140.2 Million EUR | -14.89% |
2017 | 164.73 Million EUR | -4.58% |
2016 | 172.64 Million EUR | 24.29% |
2015 | 138.9 Million EUR | -1.71% |
2014 | 141.32 Million EUR | 0.99% |
2013 | 139.93 Million EUR | -13.14% |
2012 | 161.1 Million EUR | -12.12% |
2011 | 183.31 Million EUR | -6.45% |
2010 | 195.96 Million EUR | 15.15% |
2009 | 170.17 Million EUR | 7.57% |
2008 | 158.19 Million EUR | 18.49% |
2007 | 133.51 Million EUR | 13.89% |
2006 | 117.23 Million EUR | 248.07% |
2005 | 33.68 Million EUR | -6.72% |
2004 | 36.1 Million EUR | -73.49% |
2003 | 136.19 Million EUR | 30.29% |
2002 | 104.53 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 141.22 Million EUR | -4.44% |
2024 Q3 | 150.95 Million EUR | 11.23% |
2024 Q2 | 135.72 Million EUR | -3.9% |
2023 Q4 | 147.78 Million EUR | 3.19% |
2023 Q2 | 148.38 Million EUR | -5.36% |
2023 Q1 | 156.78 Million EUR | -7.94% |
2023 FY | 147.78 Million EUR | -13.22% |
2023 Q3 | 143.21 Million EUR | -3.48% |
2022 Q2 | 183.83 Million EUR | 4.32% |
2022 Q4 | 170.3 Million EUR | 2.23% |
2022 FY | 170.3 Million EUR | -10.59% |
2022 Q1 | 176.22 Million EUR | -7.48% |
2022 Q3 | 166.59 Million EUR | -9.38% |
2021 Q4 | 190.46 Million EUR | -6.86% |
2021 FY | 190.46 Million EUR | -16.29% |
2021 Q1 | 217.57 Million EUR | -4.38% |
2021 Q2 | 207.68 Million EUR | -4.55% |
2021 Q3 | 204.48 Million EUR | -1.54% |
2020 Q2 | 248.72 Million EUR | 25.48% |
2020 Q1 | 198.22 Million EUR | 69.07% |
2020 FY | 227.53 Million EUR | 94.06% |
2020 Q4 | 227.53 Million EUR | -1.75% |
2020 Q3 | 231.58 Million EUR | -6.89% |
2019 Q4 | 117.24 Million EUR | -3.69% |
2019 Q1 | 158.6 Million EUR | 13.13% |
2019 Q2 | 133.51 Million EUR | -15.82% |
2019 Q3 | 121.74 Million EUR | -8.82% |
2019 FY | 117.24 Million EUR | -16.37% |
2018 Q4 | 140.2 Million EUR | -4.37% |
2018 FY | 140.2 Million EUR | -14.89% |
2018 Q1 | 164 Million EUR | -0.44% |
2018 Q2 | 164.48 Million EUR | 0.29% |
2018 Q3 | 146.61 Million EUR | -10.87% |
2017 Q4 | 164.73 Million EUR | -1.64% |
2017 FY | 164.73 Million EUR | -4.58% |
2017 Q3 | 167.48 Million EUR | -6.44% |
2017 Q2 | 179 Million EUR | 4.96% |
2017 Q1 | 170.54 Million EUR | -1.21% |
2016 Q1 | 152.52 Million EUR | 9.8% |
2016 Q4 | 172.64 Million EUR | 12.53% |
2016 FY | 172.64 Million EUR | 24.29% |
2016 Q2 | 161.88 Million EUR | 6.14% |
2016 Q3 | 153.41 Million EUR | -5.23% |
2015 Q2 | 150.58 Million EUR | 7.83% |
2015 Q1 | 139.64 Million EUR | -1.19% |
2015 FY | 138.9 Million EUR | -1.71% |
2015 Q3 | 168.77 Million EUR | 12.09% |
2015 Q4 | 138.9 Million EUR | -17.7% |
2014 FY | 141.32 Million EUR | 0.99% |
2014 Q4 | 141.32 Million EUR | -4.37% |
2014 Q3 | 147.78 Million EUR | -4.63% |
2014 Q2 | 154.94 Million EUR | 11.19% |
2014 Q1 | 139.35 Million EUR | -0.42% |
2013 Q2 | 154.48 Million EUR | -4.6% |
2013 FY | 139.93 Million EUR | -13.14% |
2013 Q3 | 149.21 Million EUR | -3.42% |
2013 Q4 | 139.93 Million EUR | -6.22% |
2013 Q1 | 161.94 Million EUR | 0.52% |
2012 Q2 | 185.5 Million EUR | 1.18% |
2012 Q1 | 183.33 Million EUR | 0.01% |
2012 Q3 | 177.53 Million EUR | -4.3% |
2012 FY | 161.1 Million EUR | -12.12% |
2012 Q4 | 161.1 Million EUR | -9.25% |
2011 Q4 | 183.31 Million EUR | -7.53% |
2011 FY | 183.31 Million EUR | -6.45% |
2011 Q1 | 189.82 Million EUR | -3.13% |
2011 Q2 | 198.27 Million EUR | 4.45% |
2011 Q3 | 198.24 Million EUR | -0.01% |
2010 FY | 195.96 Million EUR | 15.15% |
2010 Q1 | 175.5 Million EUR | 3.13% |
2010 Q2 | 203.63 Million EUR | 16.02% |
2010 Q3 | 201.62 Million EUR | -0.99% |
2010 Q4 | 195.96 Million EUR | -2.81% |
2009 Q4 | 170.17 Million EUR | -6.54% |
2009 FY | 170.17 Million EUR | 7.57% |
2009 Q1 | 160.73 Million EUR | 1.61% |
2009 Q3 | 182.08 Million EUR | 0.02% |
2009 Q2 | 182.05 Million EUR | 13.26% |
2008 Q4 | 158.19 Million EUR | 0.0% |
2008 FY | 158.19 Million EUR | 18.49% |
2007 FY | 133.51 Million EUR | 13.89% |
2006 FY | 117.23 Million EUR | 248.07% |
2005 FY | 33.68 Million EUR | -6.72% |
2004 FY | 36.1 Million EUR | -73.49% |
2003 FY | 136.19 Million EUR | 30.29% |
2002 FY | 104.53 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Atrys Health, S.A. | 332.45 Million EUR | 55.548% |
Biotechnologies Assets SA | 10.07 Million EUR | -1366.786% |
Laboratorios Farmaceuticos Rovi, S.A. | 256.39 Million EUR | 42.359% |